At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 90 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Quetiapine for Bipolar Disorder and Alcohol Dependence
University of Texas Southwestern Medical Center·interventional·Posted Apr 6, 2007·Updated Jul 25, 2025
In Brief
A Phase 4 clinical trial evaluating Placebo and Quetiapine for Bipolar Disorder and Alcohol Dependence. Completed, enrolled 90 participants across 1 site.
Detailed Summary
The purpose of this study is to find out whether an investigational drug called quetiapine can treat bipolar disorder, improve mood and reduce alcohol use and craving.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBipolar Disorder, Alcohol Dependence
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2007
First PostedApr 2007
Primary CompletionJul 2011
TodayJul 2026
First PostedApr 6, 2007
Enrollment StartMar 1, 2007
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 19.2 years ago
Interventions
Placebodrug
Inactive ingredient matching the active medication in appearance.
Quetiapinedrug
Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.